SLU-PP-332 is a potent small molecule agonist of estrogen-related receptor alpha (ERRa) and gamma (ERRg) – orphan nuclear receptors that are master regulators of mitochondrial biogenesis and oxidative metabolism. CAS: 2055396-63-7 | MW: 369.42 g/mol. Supplied at ≥98% purity for metabolic biology and exercise physiology research.

Research Background

ERRa and ERRg are constitutively active orphan nuclear receptors regulating gene expression for mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation – essentially controlling the transcriptional response to aerobic exercise. These receptors share target gene overlap with PGC-1a (master regulator of mitochondrial biogenesis) and are key nodes in the exercise-adaptive transcriptional network. SLU-PP-332 was identified through rational drug design targeting the ERR ligand-binding domain and has been studied as a potential exercise mimetic in preclinical models.

Mechanism of Action & Research Applications

• Mitochondrial biogenesis: Upregulation of PGC-1a target genes and increased mitochondrial content in muscle cell models
• Oxidative metabolism: Increased expression of fatty acid oxidation and electron transport chain genes
• Exercise-adaptive gene expression: Recapitulation of aerobic conditioning transcriptional signatures in sedentary animal models
• Cardiac research: ERRa/g highly expressed in heart; SLU-PP-332 studied in cardiac metabolism models

Storage & Handling

• Long-term storage: -20°C, desiccated, protected from light
• Short-term storage: 2-8°C in sealed container
• Reconstitution: High solubility in DMSO; dilute into aqueous media for cell culture (≤0.1% DMSO final); include DMSO vehicle controls

Related Research Compounds

Complementary mitochondrial/metabolic research: MOTS-C 40mg, SS-31 10mg, and NAD+ 500mg.

For research use only. Not for human or animal consumption. Not a medicinal product.